Multipeptide-based immunotherapy (DKFZ/Eberhard Karls University)

N/A

Report date: 2022/08/31 20:01:10

Base Information

Drug NameMultipeptide-based immunotherapy (DKFZ/Eberhard Karls University)
Drug Alias NameN/A
ClassificationVaccines > Development/production technology > Synthetic peptide vaccineVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGerman Consortium For Translational Cancer ResearchEberhard-Karls Universitaet TuebingenUniversity Hospital Tuebingen
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Hospital Tuebingen
Active IndicationsN/A
Inactive IndicationsProstatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A